Frau, Roberto
Traccis, Francesco
Concas, Luca
Cadeddu, Roberto
Mosher, Laura J
Nordkild, Peter
Gaikwad, Nilesh W
Bortolato, Marco
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R21 NS125654)
Article History
Received: 21 December 2022
Accepted: 26 April 2023
First Online: 2 May 2023
Declarations
:
: PN is CEO and CMO for Asarina Pharma and has a 1.2% equity stake in Asarina Pharma. MB consults for Asarina Pharmaceuticals and receives research funding from Asarina and Lundbeck Pharmaceuticals. All the other authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.